With our partner Cedars-Sinai, we’re creating a new initiative to advance precision medicine
Researchers know that people respond differently to foods, drugs, and chemicals. For example, a medication may be effective in one individual, while it makes another even more ill. Until now, we’ve had no way to test how a diet or a treatment plan would affect a person before administering it to them.
In the effort to provide clinicians with better information about their patients, we’ve announced a program with Cedars-Sinai Medical Center that combines their expertise working with stem cells together with our Organs-on-Chips technology. This Patient-on-a-Chip program holds the potential to advance the field of precision medicine and provide clinicians with a new system that more accurately predicts an individual’s response to foods, medicines, and chemicals.
The collaboration leverages innovative stem cell science from Cedars-Sinai and our Human Emulation System, which uses Organs-on-Chips technology to recreate true-to-life biology outside the body. The Human Emulation System creates an environment where cells exhibit an unprecedented level of biological function, and gives researchers the ability to control complex human biology and disease mechanisms that is not possible with other techniques.
Cedars-Sinai scientists can harvest cells from the blood or skin of participating individuals. These cells can then be reprogrammed into induced pluripotent stem cells, which can be made into any organ cell, each bearing the unique genetic fingerprint and characteristics of the individual. This process is particularly useful to recreate cells from organs like the brain, which can’t be sampled from a living individual.
By placing a patient’s cells in Organ-Chips and exposing those cells to a particular drug or series of drugs, clinicians could gain better information about how that individual would respond to treatment, avoiding the risk of administering a drug that may cause harm.